| 综述 |
|
|
|
|
| ADC药物的抗体组成及其作用靶点研究进展* |
曾弘烨,宁文静,罗文新**( ) |
| 厦门大学公共卫生学院 国家传染病诊断试剂与疫苗工程技术研究中心 厦门 361102 |
|
| Advances in the Study of Antibody Composition and Targets of ADC Drugs |
| ZENG Hong-ye,NING Wen-jing,LUO Wen-xin**() |
| National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen 361102, China |
| [1] |
Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nature Reviews Cancer, 2008, 8 (6): 473-480.
doi: 10.1038/nrc2394
pmid: 18469827
|
| [2] |
Joubert N, Beck A, Dumontet C, et al. Antibody-drug conjugates: the last decade. Pharmaceuticals (Basel, Switzerland), 2020, 13(9): 245.
|
| [3] |
Iyer U, Kadambi V J. Antibody drug conjugates:Trojan horses in the war on cancer. Journal of Pharmacological and Toxicological Methods, 2011, 64(3): 207-212.
doi: 10.1016/j.vascn.2011.07.005
pmid: 21843648
|
| [4] |
Yu J F, Song Y P, Tian W Z. How to select IgG subclasses in developing anti-tumor therapeutic antibodies. Journal of Hematology & Oncology, 2020, 13(1): 45.
|
| [5] |
Jin Y M, Schladetsch M A, Huang X T, et al. Stepping forward in antibody-drug conjugate development. Pharmacology & Therapeutics, 2022, 229: 107917.
|
| [6] |
Dean A Q, Luo S, Twomey J D, et al. Targeting cancer with antibody-drug conjugates: promises and challenges. mAbs, 2021, 13(1): 1951427.
doi: 10.1080/19420862.2021.1951427
|
| [7] |
Gomes-da-Silva L C, Kepp O, Kroemer G. Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death. OncoImmunology, 2020, 9(1): 1841393.
doi: 10.1080/2162402X.2020.1841393
|
| [8] |
Caimi P F, Ai W Y, Alderuccio J P, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. The Lancet Oncology, 2021, 22(6): 790-800.
doi: 10.1016/S1470-2045(21)00139-X
|
| [9] |
Peng Z, Liu T, Wei J, et al. Efficacy and safety of a novel anti-HER2 therapeutic antibody RC 48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study. Cancer Commun (Lond), 2021, 41(11): 1173-1182.
|
| [10] |
BusinessWire. Seagen and Genmab announce FDA accelerated approval for TIVDAKTM tisotumab vedotin-tftv in previously treated recurrent or metastatic cervical cancer. [2021-09-20]. https://www.businesswire.com/news/home/20210920005921/en/.
|
| [11] |
Beck A, Goetsch L, Dumontet C, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nature Reviews Drug Discovery, 2017, 16 (5): 315-337.
doi: 10.1038/nrd.2016.268
|
| [12] |
Walsh S J, Bargh J D, Dannheim F M, et al. Site-selective modification strategies in antibody-drug conjugates. Chemical Society Reviews, 2021, 50(2): 1305-1353.
doi: 10.1039/D0CS00310G
|
| [13] |
Kim E G, Kim K M. Strategies and advancement in antibody-drug conjugate optimization for targeted cancer therapeutics. Biomolecules & Therapeutics, 2015, 23 (6): 493-509.
|
| [14] |
Christiansen J, Rajasekaran A K. Biological impediments to monoclonal antibody-based cancer immunotherapy. Molecular Cancer Therapeutics, 2004, 3(11): 1493-1501.
pmid: 15542788
|
| [15] |
Labrijn A F, Janmaat M L, Reichert J M, et al. Bispecific antibodies: a mechanistic review of the pipeline. Nature Reviews Drug Discovery, 2019, 18 (8): 585-608.
doi: 10.1038/s41573-019-0028-1
pmid: 31175342
|
| [16] |
Carter P J, Lazar G A. Next generation antibody drugs: pursuit of the ’high-hanging fruit. Nature Reviews Drug Discovery, 2018, 17 (3): 197-223.
doi: 10.1038/nrd.2017.227
pmid: 29192287
|
| [17] |
Hamblett K J, Hammond P W, Barnscher S D, et al. ZW49, a HER2-targeted biparatopic antibody-drug conjugate for the treatment of HER2-expressing cancers. Cancer Research, 2018, 78(13 Supplement): 3914.
|
| [18] |
DaSilva J O, Yang K T, Surriga O, et al. A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade. Molecular Cancer Therapeutics, 2021, 20(10): 1966-1976.
doi: 10.1158/1535-7163.MCT-21-0009
pmid: 34315762
|
| [19] |
Lee N K, Su Y, Bidlingmaier S, et al. Manipulation of cell-type selective antibody internalization by a guide-effector bispecific design. Molecular Cancer Therapeutics, 2019, 18(6): 1092-1103.
doi: 10.1158/1535-7163.MCT-18-1313
|
| [20] |
Chomet M, Schreurs M, Nguyen M, et al. The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89 Zr-immuno-PET in xenograft bearing mice. Theranostics, 2020, 10(13): 5815-5828.
doi: 10.7150/thno.44334
|
| [21] |
Johnson M, El-Khoueiry A, Hafez N, et al. Phase I, first-in-human study of the probody therapeutic CX-2029 in adults with advanced solid tumor malignancies. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 2021, 27(16): 4521-4530.
doi: 10.1158/1078-0432.CCR-21-0194
|
| [22] |
Deonarain M P, Xue Q. Tackling solid tumour therapy with small-format drug conjugates. Antibody Therapeutics, 2020, 3(4): 237-245.
doi: 10.1093/abt/tbaa024
pmid: 33928231
|
| [23] |
Liu M M, Li L, Jin D, et al. Nanobody:a versatile tool for cancer diagnosis and therapeutics. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13(4): e1697.
|
| [24] |
Wu T T, Liu J B, Liu M M, et al. A nanobody-conjugated DNA nanoplatform for targeted platinum-drug delivery. Angewandte Chemie International Edition, 2019, 58(40): 14224-14228.
|
| [25] |
Liu M M, Zhu Y, Wu T T, et al. Nanobody-ferritin conjugate for targeted photodynamic therapy. Chemistry: A European Journal, 2020, 26(33): 7442-7450.
doi: 10.1002/chem.202000075
|
| [26] |
Fang T, Duarte J N, Ling J J, et al. Structurally defined αMHC-II nanobody-drug conjugates: a therapeutic and imaging system for B-cell lymphoma. Angewandte Chemie (International Ed in English), 2016, 55(7): 2416-2420.
doi: 10.1002/anie.201509432
|
| [27] |
Xenaki K T, Dorrestijn B, Muns J A, et al. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice. Theranostics, 2021, 11(11): 5525-5538.
doi: 10.7150/thno.57510
|
| [28] |
Baral T N, Magez S, Stijlemans B, et al. Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nature Medicine, 2006, 12 (5): 580-584.
pmid: 16604085
|
| [29] |
Collins D M, Bossenmaier B, Kollmorgen G, et al. Acquired resistance to antibody-drug conjugates. Cancers, 2019, 11(3): 394.
doi: 10.3390/cancers11030394
|
| [30] |
Turajlic S, Sottoriva A, Graham T, et al. Resolving genetic heterogeneity in cancer. Nature Reviews Genetics, 2019, 20 (7): 404-416.
doi: 10.1038/s41576-019-0114-6
pmid: 30918367
|
| [31] |
Stokke J L, Bhojwani D. Antibody-drug conjugates for the treatment of acute pediatric leukemia. Journal of Clinical Medicine, 2021, 10(16): 3556.
doi: 10.3390/jcm10163556
|
| [32] |
Costa R L B, Czerniecki B J. Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond. Npj Breast Cancer, 2020, 6: 10.
doi: 10.1038/s41523-020-0153-3
|
| [33] |
Shitara K, Bang Y J, Iwasa S, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. The New England Journal of Medicine, 2020, 382(25): 2419-2430.
doi: 10.1056/NEJMoa2004413
pmid: 32469182
|
| [34] |
Siena S, Bartolomeo M D, Raghav K, et al. rastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. The Lancet Oncology, 2021, 22(6): 779-789.
doi: 10.1016/S1470-2045(21)00086-3
|
| [35] |
Li B T, Shen R L, Buonocore D, et al. Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2018, 36(24): 2532-2537.
doi: 10.1200/JCO.2018.77.9777
|
| [36] |
Sheng X N, Yan X Q, Wang L, et al. Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 2021, 27(1): 43-51.
doi: 10.1158/1078-0432.CCR-20-2488
|
| [37] |
Modi S N, Park H, Murthy R K, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase ib study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2020, 38(17): 1887-1896.
doi: 10.1200/JCO.19.02318
|
| [38] |
Shitara K, Iwata H, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. The Lancet Oncology, 2019, 20(6): 827-836.
doi: 10.1016/S1470-2045(19)30088-9
|
| [39] |
Kang J C, Sun W, Khare P, et al. Engineering a HER2-specific antibody-drug conjugate to increase lysosomal delivery and therapeutic efficacy. Nature Biotechnology, 2019, 37 (5): 523-526.
doi: 10.1038/s41587-019-0073-7
|
| [40] |
Li J Y, Perry S R, Muniz-Medina V, et al. A biparatopic HER2-targeting antibody-drug conjugate induces tumor regression in primary models refractory to or ineligible for HER2-targeted therapy. Cancer Cell, 2016, 29(1): 117-129.
doi: 10.1016/j.ccell.2015.12.008
|
| [41] |
Nordstrom J L, Gorlatov S, Zhang W J, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Research, 2011, 13(6): R123.
doi: 10.1186/bcr3069
|
| [42] |
Bang Y J, Giaccone G, Im S A, et al. First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. . Annals of Oncology, 2017, 28(4): 855-861.
doi: 10.1093/annonc/mdx002
pmid: 28119295
|
| [43] |
Kang X H, Zhou L, Jian Y M, et al. Effectiveness of antibody-drug conjugate (ADC): results of in vitro and in vivo studies. Medical Science Monitor, 2018, 24: 1408-1416.
doi: 10.12659/MSM.908971
|
| [44] |
Gan H K, Burgess A W, Clayton A H A, et al. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Research, 2012, 72(12): 2924-2930.
doi: 10.1158/0008-5472.CAN-11-3898
|
| [45] |
Cleary J M, Reardon D A, Azad N, et al. A phase 1 study of ABT-806 in subjects with advanced solid tumors. Investigational New Drugs, 2015, 33(3): 671-678.
doi: 10.1007/s10637-015-0234-6
pmid: 25895099
|
| [46] |
Chia P L, Parakh S, Tsao M S, et al. Targeting and efficacy of novel MAb806-antibody-drug conjugates in malignant mesothelioma. Pharmaceuticals (Basel, Switzerland), 2020, 13(10): 289.
|
| [47] |
Phillips A C, Boghaert E R, Vaidya K S, et al. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Molecular Cancer Therapeutics, 2016, 15(4): 661-669.
doi: 10.1158/1535-7163.MCT-15-0901
pmid: 26846818
|
| [48] |
Park K, Haura E B, Leighl N B, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2021, 39(30): 3391-3402.
doi: 10.1200/JCO.21.00662
|
| [49] |
Goldenberg D M, Cardillo T M, Govindan S V, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget, 2015, 6(26): 22496-22512.
pmid: 26101915
|
| [50] |
Bardia A, Hurvitz S A, Tolaney S M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. The New England Journal of Medicine, 2021, 384(16): 1529-1541.
doi: 10.1056/NEJMoa2028485
|
| [51] |
TROP2 ADC intrigues in NSCLC. Cancer Discovery, 2021, 11(5): OF5.
|
| [52] |
Scaranti M, Cojocaru E, Banerjee S, et al. Exploiting the folate receptor α in oncology. Nature Reviews Clinical Oncology, 2020, 17 (6): 349-359.
doi: 10.1038/s41571-020-0339-5
pmid: 32152484
|
| [53] |
Moore K N, Oza A M, Colombo N, et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Annals of Oncology, 2021, 32(6): 757-765.
doi: 10.1016/j.annonc.2021.02.017
pmid: 33667670
|
| [54] |
Haikala H M, Jänne P A. Thirty years of HER3: from basic biology to therapeutic interventions. Clinical Cancer Research, 2021, 27(13): 3528-3539.
doi: 10.1158/1078-0432.CCR-20-4465
pmid: 33608318
|
| [55] |
Yonesaka K. HER2-/ HER3-targeting antibody-drug conjugates for treating lung and colorectal cancers resistant to EGFR inhibitors. Cancers, 2021, 13(5): 1047.
doi: 10.3390/cancers13051047
|
| [56] |
Powles T, Rosenberg J E, Sonpavde G P, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. The New England Journal of Medicine, 2021, 384(12): 1125-1135.
doi: 10.1056/NEJMoa2035807
|
| [57] |
M-Rabet M, Cabaud O, Josselin E, et al. Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. Annals of Oncology, 2017, 28(4): 769-776.
doi: 10.1093/annonc/mdw678
pmid: 27998973
|
| [58] |
Yap M L, McFadyen J D, Wang X W, et al. Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases. Theranostics, 2019, 9(4): 1154-1169.
doi: 10.7150/thno.29146
|
| [59] |
Szot C, Saha S, Zhang X M, et al. Tumor stroma-targeted antibody-drug conjugate triggers localized anticancer drug release. The Journal of Clinical Investigation, 2018, 128(7): 2927-2943.
doi: 10.1172/JCI120481
|
| [60] |
Breij E C W, de Goeij B E C G, Verploegen S, et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Research, 2014, 74(4): 1214-1226.
doi: 10.1158/0008-5472.CAN-13-2440
|
| [61] |
Coleman R L, Lorusso D, Gennigens C, et al. fficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. The Lancet Oncology, 2021, 22(5): 609-619.
doi: 10.1016/S1470-2045(21)00056-5
|
| [62] |
Bobrowicz M, Kubacz M, Slusarczyk A, et al. CD37 in B cell derived tumors-more than just a docking point for monoclonal antibodies. International Journal of Molecular Sciences, 2020, 21(24): 9531.
doi: 10.3390/ijms21249531
|
| [63] |
Hicks S W, Lai K C, Gavrilescu L C, et al. The antitumor activity of IMGN529, a CD37-targeting antibody-drug conjugate, is potentiated by rituximab in non-Hodgkin lymphoma models. Neoplasia, 2017, 19(9): 661-671.
doi: 10.1016/j.neo.2017.06.001
|
| [64] |
Wajant H. Therapeutic targeting of CD70 and CD27. Expert Opinion on Therapeutic Targets, 2016, 20(8): 959-973.
doi: 10.1517/14728222.2016.1158812
|
| [65] |
Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends in Molecular Medicine, 2014, 20(6): 332-342.
doi: 10.1016/j.molmed.2014.02.007
|
| [66] |
Detappe A, Mathieu C, Jin C N, et al. Anti-MUC1-C antibody-conjugated nanoparticles potentiate the efficacy of fractionated radiation therapy. International Journal of Radiation Oncology Biology Physics, 2020, 108(5): 1380-1389.
doi: 10.1016/j.ijrobp.2020.06.069
|
| [67] |
Wu G, Li L, Qiu Y X, et al. A novel humanized MUC 1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer. Acta Biochimica et Biophysica Sinica, 2021, 53(12): 1625-1639.
doi: 10.1093/abbs/gmab141
|
| [68] |
Vaisitti T, Arruga F, Vitale N, et al. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. Blood, 2021, 137(24): 3365-3377.
doi: 10.1182/blood.2020008404
pmid: 33512452
|
| [69] |
Hu E Y, Do P, Goswami S, et al. The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. Blood Advances, 2021, 5(16): 3152-3162.
doi: 10.1182/bloodadvances.2020003276
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
